Equities Research Analysts’ Updated EPS Estimates for December 19th (ACET, ARBB, ARMP, BIRK, BLFS, BNZL, BRZE, BVC, CGTX, CHDN)

Equities Research Analysts’ updated eps estimates for Thursday, December 19th:

Adicet Bio (NASDAQ:ACET) had its neutral rating reiterated by analysts at HC Wainwright.

Arbuthnot Banking Group (LON:ARBB) had its house stock rating reiterated by analysts at Shore Capital.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) had its buy rating reissued by analysts at HC Wainwright. They currently have a $7.00 price target on the stock.

Birkenstock (NYSE:BIRK) had its outperform rating reiterated by analysts at Telsey Advisory Group. They currently have a $70.00 price target on the stock.

BioLife Solutions (NASDAQ:BLFS) had its buy rating reissued by analysts at Benchmark Co.. They currently have a $30.00 price target on the stock.

Bunzl (LON:BNZL) had its buy rating reissued by analysts at Shore Capital.

Braze (NASDAQ:BRZE) had its outperform rating reissued by analysts at William Blair.

BATM Advanced Communications (LON:BVC) had its house stock rating reissued by analysts at Shore Capital.

Cognition Therapeutics (NASDAQ:CGTX) had its buy rating reissued by analysts at Chardan Capital. Chardan Capital currently has a $11.00 target price on the stock.

Churchill Downs (NASDAQ:CHDN) had its market outperform rating reaffirmed by analysts at JMP Securities. JMP Securities currently has a $166.00 price target on the stock.

Celldex Therapeutics (NASDAQ:CLDX) had its buy rating reissued by analysts at HC Wainwright. They currently have a $80.00 price target on the stock.

Clene (NASDAQ:CLNN) had its buy rating reaffirmed by analysts at D. Boral Capital. The firm currently has a $23.00 price target on the stock.

Darden Restaurants (NYSE:DRI) had its equal weight rating reaffirmed by analysts at Stephens. Stephens currently has a $164.00 price target on the stock.

Elevation Oncology (NASDAQ:ELEV) had its market outperform rating reissued by analysts at JMP Securities. JMP Securities currently has a $7.00 target price on the stock.

e.l.f. Beauty (NYSE:ELF) had its buy rating reiterated by analysts at DA Davidson. DA Davidson currently has a $170.00 target price on the stock.

General Mills (NYSE:GIS) had its sector perform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $70.00 price target on the stock.

Grocery Outlet (NASDAQ:GO) had its market perform rating reaffirmed by analysts at Telsey Advisory Group. They currently have a $18.00 price target on the stock.

Structure Therapeutics (NASDAQ:GPCR) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $80.00 price target on the stock.

Great Portland Estates (LON:GPE) had its hold rating reiterated by analysts at Berenberg Bank. The firm currently has a GBX 382 ($4.80) price target on the stock.

Healthcare Services Group (NASDAQ:HCSG) had its buy rating reiterated by analysts at Benchmark Co.. They currently have a $17.00 price target on the stock.

Hologic (NASDAQ:HOLX) had its buy rating reiterated by analysts at Needham & Company LLC. They currently have a $90.00 price target on the stock.

Imunon (NASDAQ:IMNN) had its buy rating reissued by analysts at D. Boral Capital. D. Boral Capital currently has a $29.00 price target on the stock.

Imunon (NASDAQ:IMNN) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $12.00 target price on the stock.

Jabil (NYSE:JBL) had its buy rating reaffirmed by analysts at Stifel Nicolaus. They currently have a $160.00 target price on the stock, up from their previous target price of $150.00.

Klaviyo (NYSE:KVYO) had its outperform rating reiterated by analysts at William Blair.

Lennar (NYSE:LEN) had its neutral rating reaffirmed by analysts at Wedbush. Wedbush currently has a $164.00 price target on the stock.

NICE (NASDAQ:NICE) had its hold rating reaffirmed by analysts at Jefferies Financial Group Inc.. The firm currently has a $200.00 target price on the stock, down from their previous target price of $215.00.

UiPath (NYSE:PATH) had its hold rating reiterated by analysts at Needham & Company LLC.

Penguin Solutions (NASDAQ:PENG) had its buy rating reaffirmed by analysts at Rosenblatt Securities. They currently have a $27.00 target price on the stock.

Palatin Technologies (NYSEAMERICAN:PTN) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $17.00 target price on the stock.

Pactiv Evergreen (NASDAQ:PTVE) had its sector perform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $18.00 target price on the stock, up from their previous target price of $14.00.

Chicago Atlantic Real Estate Finance (NASDAQ:REFI) had its market outperform rating reissued by analysts at JMP Securities. JMP Securities currently has a $20.00 price target on the stock.

Sezzle (NASDAQ:SEZL) had its buy rating reiterated by analysts at B. Riley. The firm currently has a $372.00 price target on the stock, up from their previous price target of $353.00.

Sangamo Therapeutics (NASDAQ:SGMO) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $10.00 price target on the stock.

Similarweb (NYSE:SMWB) had its outperform rating reiterated by analysts at William Blair.

Sarepta Therapeutics (NASDAQ:SRPT) had its sell rating reaffirmed by analysts at HC Wainwright. They currently have a $75.00 price target on the stock.

Savara (NASDAQ:SVRA) had its market outperform rating reaffirmed by analysts at JMP Securities. JMP Securities currently has a $9.00 price target on the stock.

Tripadvisor (NASDAQ:TRIP) had its neutral rating reiterated by analysts at DA Davidson. The firm currently has a $16.00 target price on the stock.

Trade Desk (NASDAQ:TTD) had its outperform rating reissued by analysts at Wedbush. Wedbush currently has a $135.00 target price on the stock.

Texas Roadhouse (NASDAQ:TXRH) had its outperform rating reiterated by analysts at Wedbush. Wedbush currently has a $200.00 target price on the stock.

Uranium Royalty (NASDAQ:UROY) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $7.70 price target on the stock.

Viridian Therapeutics (NASDAQ:VRDN) had its equal weight rating reissued by analysts at Wells Fargo & Company. The firm currently has a $27.00 target price on the stock, down from their previous target price of $37.00.

Verastem (NASDAQ:VSTM) had its buy rating reissued by analysts at HC Wainwright. They currently have a $7.00 target price on the stock.

V2X (NYSE:VVX) had its sector perform rating reissued by analysts at Royal Bank of Canada. The firm currently has a $58.00 target price on the stock, down from their previous target price of $70.00.

Zeta Global (NYSE:ZETA) had its outperform rating reiterated by analysts at William Blair.